Studying attention and reward sensitivity in adults with bipolar disorder
Official title: Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder and Different Psychiatric Comorbidities: An Eye-Tracking Study
Run by University Hospitals Cleveland Medical Center · NCT03829787 · Data updated 2026-11-12
This study is testing how attention and sensitivity to rewards affect adults with bipolar disorder to better understand their mental health challenges.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | March 27, 2019 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT03829787 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a diagnosis of bipolar I or II disorder, currently experiencing a depressive episode or in remission.
✕Probably not a fit
Patients with significant structural brain lesions or those not meeting the inclusion criteria for bipolar disorder will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate attentional biases, reward sensitivity, and cognitive control in adults diagnosed with bipolar disorder, utilizing advanced eye-tracking technology. Participants will include individuals with bipolar disorder, with or without comorbid anxiety or substance use disorders. The study will assess how these factors influence cognitive processes in this population, providing insights into their mental health challenges. The research will involve detailed assessments to ensure participants meet specific diagnostic criteria.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cognitive processes in bipolar disorder, potentially leading to improved treatment strategies.
How similar studies have gone: While similar studies have explored cognitive processes in bipolar disorder, this specific approach using eye-tracking technology is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
1. Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder 1. Inclusion Criteria for Group 1: i. Male or female, age 18 or older ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI) iii. Currently in a depressive episode or currently in remission from a mood episode iv. Young Mania Rating Scale total score ≤ 8 v. In the opinion of the investigator, capable of understanding and complying with protocol requirements vi. In the opinion of the investigator, has the competency to understand and sign the informed consent vii. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion b. Exclusion Criteria for Group 1: i. Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment. iv. Currently pregnant or planning to become pregnant v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription vi. Currently taking any steroids, stimulants, or opioid pain killers. vii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit. viii. Has had electroconvulsive therapy (ECT) treatment within the last 6 months. 2. Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) a. Inclusion Criteria for Group 2: i. Male or female, age 18 or older ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI) iii. Currently in a depressive episode or currently in remission from a mood episode iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI) v. Hamilton Anxiety Rating Scale total score ≥ 18 vi. Young Mania Rating Scale total score ≤ 8 vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements viii. In the opinion of the investigator, has the competency to understand and sign the informed consent ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion b. Exclusion Criteria for Group 2: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD) iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment. v. Currently pregnant or planning to become pregnant vi. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription vii. Currently taking any steroids, stimulants, or opioid pain killers. viii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine ix. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit. x. Has had ECT treatment within the last 6 months. 3. Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder a. Inclusion Criteria for Group 3: i. Male or female, age 18 or older ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI) iii. Meets diagnostic criteria for a substance use disorder within the last 3 months iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI) v. Currently in a depressive episode or currently in remission from a mood episode vi. Hamilton Anxiety Rating Scale total score ≥ 18 vii. Young Mania Rating Scale total score ≤ 8 viii. In the opinion of the investigator, capable of understanding and complying with protocol requirements ix. In the opinion of the investigator, has the competency to understand and sign the informed consent x. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion b. Exclusion Criteria for Group 3: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD) iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment. v. Intoxicated or in acute withdrawal state. vi. Currently pregnant or planning to become pregnant. vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit. viii. Has had ECT treatment within the last 6 months. 4. Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder a. Inclusion Criteria for Group 4: i. Male or female, age 18 or older ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI) iii. Meets diagnostic criteria for a substance use disorder within the last 3 months iv. Currently in a depressive episode or currently in remission from a mood episode v. Young Mania Rating Scale total score ≤ 8 vi. Hamilton Anxiety Rating Scale total score ≤ 12 vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements viii. In the opinion of the investigator, has the competency to understand and sign the informed consent ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion b. Exclusion Criteria for Group 4: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD) iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment. v. Intoxicated or in an acute withdrawal state vi. Currently pregnant or planning to become pregnant. vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit. viii. Has had ECT treatment within the last 6 months. 5. Inclusion and exclusion criteria for Group 5: Healthy Volunteers 1. Inclusion criteria for Group 5: i. Male or female, age 18 or older ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements iii. In the opinion of the investigator, has the competency to understand and sign the informed consent iv. Physically healthy as determined by research psychiatrist v. Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI) b. Exclusion Criteria for Group 5: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Any psychiatric disorder including any severe personality disorder iv. Currently pregnant or planning to become pregnant v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription vi. Currently taking any steroids, stimulants, or opioid pain killers. vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
Where it's running
-
University Hospitals Cleveland Medical Center - Mood Disorders Program
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Keming Gao, MD, PhD — University Hospitals Cleveland Medical Center
- Study coordinator: Nicole Jones
- Email: mdp@uhhospitals.org
- Phone: 216/844-2862
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT
40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.
-
7T MRI and visual perception markers for severe mood and psychotic disorders
This project tests whether 7‑tesla MRI scans combined with visual perception tests can identify brain markers linked to diagnosis and treatment outcomes in adults with major depressive disorder, bipolar disorder, or schizophrenia.
-
Emotional Eating, Sleep Quality, Mental State, and Metabolic Syndrome in Psychiatric Patients
This study tests how mood, sleep, and emotional eating relate to metabolic syndrome in people with schizophrenia or bipolar disorder.
-
À deux, c'est mieux — group program to improve romantic relationships for young adults with severe mental illness
This program will try a 12-week, small-group course to help single adults with severe mental illness build skills for dating, communication, and closer social relationships.
-
Brenipatide for adults with bipolar disorder (RENEW-Bipolar-1)
This trial will test whether adding brenipatide to standard bipolar medications can delay worsening of symptoms in adults with bipolar I or II.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.